4-bromo-2,3,6-trimethylanisole | 876389-28-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-bromo-2,3,6-trimethylanisole
• 英文别名: 1-bromo-4-methoxy-2,3,5-trimethyl-benzene；1-bromo-4-methoxy-2,3,5-trimethylbenzene
• CAS: 876389-28-5
• 化学式: C₁₀H₁₃BrO
• 分子量: 229.117
• InChiKey: DVMARCGMLVDXLV-UHFFFAOYSA-N

物化性质

• 沸点：
  269.7±35.0 °C(Predicted)
• 密度：
  1.283±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  4-bromo-2,3,6-trimethylanisole 在 喹啉 、 sodium tetrahydroborate 、 magnesium 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 3.5h， 生成 5-methoxy-2,4,6,7-tetramethyl-2,3-dihydrobenzo[b]selenophene
  参考文献：
  名称：

  可再生的断裂链2,3-二氢苯并[ b ]硒烯-5-醇抗氧化剂

  摘要：

  通过对适当取代的烯丙基4-甲氧基苯基硒化物进行微波诱导的硒基-克莱森重排/分子内马氏化学加氢精制，然后由三溴化硼诱导的O-去甲基化，制备一系列2,3-二氢苯并[ b ]硒烯-5-醇抗氧化剂。测定了新型抗氧化剂在水相中含有N-乙酰半胱氨酸作为硫醇还原剂的水/氯苯两相体系中抑制亚油酸引发的亚油酸过氧化的能力。由过氧化抑制率R inh决定的抗氧化效率随甲基取代的增加而增加（R inh = 46-26μM/ h），但没有一种化合物能与α-生育酚相匹配（R inh = 22μM/ h）。在硫醇再生剂存在下，由抑制时间T inh确定的可再生性随甲基取代的增加而降低。因此，在未取代的化合物5a抑制过氧化超过320分钟的条件下，α-生育酚作用90分钟，三甲基化抗氧化剂5g作用仅60分钟。使用抗氧化剂5a在过氧化过程中以一定间隔对水相进行取样显示，N-乙酰基半胱氨酸随时间被连续氧化为相应的二硫化物。在没有再

  DOI：

  10.1021/jo0700023
• 作为产物：
  描述：

  2,3,6-三甲基苯酚 在 溴 、 potassium carbonate 作用下， 以 二氯甲烷 、 丙酮 为溶剂， 生成 4-bromo-2,3,6-trimethylanisole
  参考文献：
  名称：

  Synthesis and Antioxidant Profile of all-rac-α-Selenotocopherol

  摘要：

  all-rac-alpha-Selenotocopherol (6c) has been synthesized in 11 steps in 6.6% total yield. Key steps include chloromethylation to approach the persubstituted aromatic 9b and cyclization of alcohol precursor 10 by radical homolytic substitution at selenium to form the selenotocopherol heterocycle. Determination of the OH bond dissociation enthalpy (BDE) of 6c by electron paramagnetic resonance (EPR) equilibration techniques gave a value of 78.1 +/- 0.3 kcal mol(-1), approximately I kcal mol(-1) higher than that of a-tocopherol. Kinetic studies performed by measuring oxygen uptake of the induced oxidation of styrene in the presence of an antioxidant showed that selenotocopherol (6c) was a slightly poorer inhibitor than (x-tocopherol, in agreement with the BDE values. In contrast to simpler setenotocopherol analogues, 6c was not regenerable in the presence of a stoichiometric coreductant in a two-phase lipid peroxidation model.

  DOI：

  10.1021/jo052133e

文献信息

• Chiral phosphorous compounds
  申请人：Celtice Catalysts Limited, Nova UCD

  公开号：US08067642B2

  公开（公告）日：2011-11-29

  The present invention provides P-chiral compounds of general formulae (II) and (III): in formula (II) at least one of R21, R25, R26 and R30 is independently selected from CM alkyl, CF3, C1-4 alkoxy, phenyl and benzyloxy and the remaining substituents selected from R21, R25, R26 and R30 are hydrogen; at least one of R22, R24, R27 and R29 are independently selected from C1-14 alkyl, CF3, C1-14 alkoxy, phenyl and benzyloxy and the remaining substituents selected, from R22, R24, R27 and R29 are hydrogen; and R23 and R28 are independently selected from hydrogen, CM alkyl, CF3, C1-14 alkoxy, phenyl and benzyloxy; in formula (III) at least one of R21, R25, R26 and R30 is independently selected from phenyl and benzyloxy and the remaining substituents selected from R21, R25, R−26 and R30 are hydrogen; and R22, R−23 R24, R27, R28 and R29 are independently selected from hydrogen, C1-14 alkyl, CF3, C1-14 alkoxy, phenyl and benzyloxy.

  本发明提供了一般式（II）和（III）的P-手性化合物：在式（II）中，R21、R25、R26和R30中至少一个独立地选自CM烷基、CF3、C1-4烷氧基、苯基和苄氧基，其余取代基选自R21、R25、R26和R30为氢；R22、R24、R27和R29中至少一个独立地选自C1-14烷基、CF3、C1-14烷氧基、苯基和苄氧基，其余取代基选自R22、R24、R27和R29为氢；R23和R28独立地选自氢、CM烷基、CF3、C1-14烷氧基、苯基和苄氧基；在式（III）中，R21、R25、R26和R30中至少一个独立地选自苯基和苄氧基，其余取代基选自R21、R25、R-26和R30为氢；R22、R-23、R24、R27、R28和R29独立地选自氢、C1-14烷基、CF3、C1-14烷氧基、苯基和苄氧基。
• CHIRAL PHOSPHOROUS COMPOUNDS
  申请人：Gilheany Declan

  公开号：US20100168456A1

  公开（公告）日：2010-07-01

  The present invention provides P-chiral compounds of general formulae (II) and (III): in formula (II) at least one of R 21 , R 25 , R 26 and R 30 is independently selected from CM alkyl, CF 3 , C 1-4 alkoxy, phenyl and benzyloxy and the remaining substituents selected from R 21 , R 25 , R 26 and R 30 are hydrogen; at least one of R 22, R 24, R 27 and R 29 are independently selected from C 1-14 alkyl, CF 3, C 1-14 alkoxy, phenyl and benzyloxy and the remaining substituents selected, from R 22 , R 24, R 27 and R 29 are hydrogen; and R 23 and R28 are independently selected from hydrogen, CM alkyl, CF 3 , C 1-14 alkoxy, phenyl and benzyloxy; in formula (III) at least one of R 21 , R 25 , R 26 and R 30 is independently selected from phenyl and benzyloxy and the remaining substituents selected from R 21 , R 25 , R— 26 and R 30 are hydrogen; and R 22 , R— 23 R 24, R 27 , R 28 and R 29 are independently selected from hydrogen, C 1-14 alkyl, CF 3 , C 1-14 alkoxy, phenyl and benzyloxy.

  本发明提供了一般式（II）和（III）的P-手性化合物：在式（II）中，R21、R25、R26和R30中至少有一个是独立选择的CM烷基，CF3，C1-4烷氧基，苯基和苄氧基，其余取代基选择自R21、R25、R26和R30为氢；R22、R24、R27和R29中至少有一个是独立选择的C1-14烷基，CF3，C1-14烷氧基，苯基和苄氧基，其余取代基选择自R22、R24、R27和R29为氢；R23和R28独立选择自氢，CM烷基，CF3，C1-14烷氧基，苯基和苄氧基；在式（III）中，R21、R25、R26和R30中至少有一个是独立选择的苯基和苄氧基，其余取代基选择自R21、R25、R-26和R30为氢；R22、R-23、R24、R27、R28和R29独立选择自氢，C1-14烷基，CF3，C1-14烷氧基，苯基和苄氧基。
• FIBRIC ACID COMPOUND AND MEDICAL USE THEREOF
  申请人：Beijing Wholesomeyird Sci & Tech Co., Ltd.

  公开号：EP3842410A1

  公开（公告）日：2021-06-30

  A fibric acid compound, pharmaceutically acceptable salts or esters, stereoisomers, prodrugs, hydrates, solvates, and crystal forms thereof, metabolite forms thereof or any combination or mixture thereof; a pharmaceutical composition containing the compound, the pharmaceutically acceptable salts or esters, stereoisomers, prodrugs, hydrates, solvates, and crystal forms thereof, the metabolite forms thereof or any combination or mixture thereof; and medical use of the compound, the pharmaceutically acceptable salts or esters, stereoisomers, prodrugs, hydrates, solvates, and crystal forms thereof, the metabolite forms thereof or any combination or mixture thereof. These can be used for preventing and/or treating metabolic diseases, such as metabolic syndromes, non-alcoholic fatty liver diseases, and/or diabetes.

  一种纤维酸化合物、其药学上可接受的盐或酯、立体异构体、原药、水合物、溶 液物和晶体形式、其代谢物形式或其任何组合或混合物；一种含有该化合物、其药 学上可接受的盐或酯、立体异构体、原药、水合物、溶液物和晶体形式、其代谢物 形式或其任何组合或混合物的药物组合物；化合物、其药学上可接受的盐或酯、立体异构体、原药、水合物、溶液和晶体形式、其代谢物形式或其任何组合或混合物的医疗用途。这些药物可用于预防和/或治疗代谢性疾病，如代谢综合征、非酒精性脂肪肝和/或糖尿病。
• WO2008/117054
  申请人：——

  公开号：——

  公开（公告）日：——
• CHIRAL DIPHOSPINES, METHODS FOR THEIR PREPARATION, TRANSITION METAL COMPLEXES COMPRISING THEM AND USE IN CHIRAL SYNTHESIS
  申请人：Celtic Catalysts Limited

  公开号：EP2139905A2

  公开（公告）日：2010-01-06